Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sotatercept in Cpc-PH Due to HFpEF (CADENCE)
NCT04945460Phase 2Completed
- Start
- Dec 2021
- Primary completion
- Sep 2025
- Modality
- Fc-Fusion Proteins
- Countries
- 12
01
Overview
Phase 2, randomised, double-blind trial of sotatercept in pulmonary hypertension (PH) (3 arms). Primary endpoint: Pulmonary Vascular Resistance at 24 weeks. Started Dec 2021; status: completed.
02
Drugs
sotatercept
03
Conditions
pulmonary hypertension (PH)
Beyond the preview
Go deeper on NCT04945460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04945460.